An epidemiologic study on PD-L1 expression combined with clinical observation in the Chinese MIUBC patients.

Trial Identifier: D9012R00001
Sponsor: AstraZeneca
NCTID:: NCT03433924
Start Date: May 2020
Primary Completion Date: March 2023
Study Completion Date: March 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China Beijing, China, 100034
China Beijing, China, 100730
China Changchun, China, 130021
China Changsha, China, 410013
China Chengdu, China, 610041
China Guangzhou, China, 510120
China Guangzhou, China, 510060
China Hangzhou, China, 310014
China Jinan, China, 250012
China Meizhou, China
China Nanjing, China, 2100008
China Shanghai, China, 200032
China Shanghai, China, 200072
China Shenyang, China, 110001
China Wuhan, China, CN-430030
China Xiamen, China, 361003
China Zhengzhou, China, 450052